NCT05255094View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

464

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions
Hyperlipidemia
Interventions
BIOLOGICAL

AK102

Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

BIOLOGICAL

AK102

Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

DRUG

Placebo

Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

DRUG

Placebo

Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY